Author:
Soman Rajeev,Sirsat Rasika,Sunavala Ayesha,Punatar Neha,Mehta Jugal,Rodrigues Camilla,Veeraraghavan Balaji
Publisher
Springer Science and Business Media LLC
Reference14 articles.
1. Karlowsky JA, Hackel MA, Bouchillon SK, Sahm DF (2020) In Vitro Activity of WCK 5222 (Cefepime-Zidebactam) against Worldwide Collected Gram-negative Bacilli not susceptible to Carbapenems. Antimicrob Agents Chemother 64(12):e01432–e01420
2. Lee YL, Hsueh PR (2023) Poor in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam against carbapenem-resistant Pseudomonas aeruginosa in India: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2018–2021. J Infect 87(1):e1–e4
3. Shanthi M, Sekar U, Kamalanathan A, Sekar B (2014) Detection of New Delhi metallo beta lactamase-1 (NDM-1) carbapenemase in Pseudomonas aeruginosa in a single centre in southern India. Indian J Med Res 140:546–550
4. Jorth P, McLean K, Ratjen A, Secor PR, Bautista GE, Ravishankar S et al (2017) Evolved Aztreonam Resistance is multifactorial and can produce hypervirulence in Pseudomonas aeruginosa. mBio 8(5):e00517–e00517
5. Timsit JF, Paul M, Shields RK, Echols R, Baba T, Yamano Y et al (2022) Cefiderocol for the Treatment of Infections due to Metallo-B-lactamase-producing pathogens in the CREDIBLE-CR and APEKS-NP phase 3 Randomized studies. Clin Infect Dis 75(6):1081–1084
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献